z-logo
open-access-imgOpen Access
Testosterone augments polyphenol‐induced DNA damage response in prostate cancer cell line, LNCaP
Author(s) -
Ide Hisamitsu,
Yu Jingsong,
Lu Yan,
China Toshiyuki,
Kumamoto Tomoka,
Koseki Tatsuro,
Muto Satoru,
Horie Shigeo
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01791.x
Subject(s) - lncap , curcumin , dna damage , prostate cancer , cancer research , poly adp ribose polymerase , isoflavones , endocrinology , prostate , medicine , biology , chemistry , cancer , pharmacology , biochemistry , dna , polymerase
Recently, we reported that combined ingestion of soy isoflavones and curcumin significantly decreased the serum level of prostate‐specific antigen based on a randomized placebo‐controlled double‐blind clinical study. We investigated whether these polyphenols inhibited the proliferation of prostate cancer cells by activating a DNA damage response. The effects of isoflavones and curcumin on the expression and phosphorylation of ataxia‐telangiectasia‐mutated kinase (ATM), histone H2AX variant (H2AX) and checkpoint kinase2 (Chk2) were examined in LNCaP cells. The induction of apoptosis in LNCaP cells was evaluated by poly(ADP‐ribose) polymerase (PARP) cleavage. Furthermore, the effects of a testosterone supplement on modulation of the DNA damage response were examined. Combined treatment of isoflavones and curcumin additively suppressed cellular proliferation and induced phosphorylation of ATM, histone H2AX, Chk2 and p53. Testosterone augmented the activation of the DNA damage response and PARP cleavage induced by curcumin. Our results indicate that activation of the DNA damage response by polyphenols might suppress the malignant transformation of prostate cancer. In addition, testosterone, when combined with curcumin, may have suppressive effects on the progression of prostate cancer. ( Cancer Sci 2011; 102: 468–471)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here